Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20
12:00pm, Friday, 29'th May 2020
― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease.
— First NDA filing of savolitinib globally — — Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — LONDON, May 29, 2020 --.
Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment
08:04am, Tuesday, 26'th May 2020
Hutchison China MediTech (HCM) and BeiGene (BGNE) have now entered into a clinical collaboration agreement for the treatment of various solid tumor cancers.The collaboration will evaluate the safety,
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
06:00am, Tuesday, 26'th May 2020
– Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China.
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
06:00am, Thursday, 14'th May 2020
LONDON, May 14, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib,.
SE Asia Stocks-Rise as China signals more policy measures to support economy
04:17am, Monday, 11'th May 2020
* Thai shares rise 1.7% * Indonesia mulls reopening plans * Malaysian markets closed for holiday By Pranav A K May 11 (Reuters) - Southeast Asian stock markets rose on Monday, with Thai stocks lea
Chi-Med to Attend Upcoming Investor Conferences
08:12am, Friday, 08'th May 2020
LONDON, May 08, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will.
HUTCHISON CHINA/S (NASDAQ:HCM) Upgraded by BidaskClub to Strong-Buy
09:30am, Thursday, 30'th Apr 2020
HUTCHISON CHINA/S (NASDAQ:HCM) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Thursday, BidAskClub reports. A num
HUTCHISON CHINA/S (NASDAQ:HCM) Upgraded at BidaskClub
06:32am, Saturday, 25'th Apr 2020
BidaskClub upgraded shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, BidAskClub reports. Several other equities re
Should You Worry About Hutchison China MediTech Limited's (LON:HCM) CEO Pay?
07:12am, Thursday, 23'rd Apr 2020
Christian Hogg became the CEO of Hutchison China MediTech Limited (LON:HCM) in 2006. This analysis aims first to...
Edison Issues ADR Update on Hutchison China MediTech (HCM)
12:15pm, Wednesday, 22'nd Apr 2020
LONDON, UK / ACCESSWIRE / April 22, 2020 / Notwithstanding the COVID-19 pandemic challenges, Hutchison China MediTech (NASDAQ:HCM) remains on track for potential approval and launches of two additiona
Chi-Med Highlights Presentations of Surufatinib at the UpcomingAACR VirtualAnnualMeetings
08:00am, Wednesday, 22'nd Apr 2020
LONDON, April 22, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib.
Bank of New York Mellon Corp Decreases Stake in HUTCHISON CHINA/S (NASDAQ:HCM)
08:58am, Tuesday, 21'st Apr 2020
Bank of New York Mellon Corp trimmed its position in shares of HUTCHISON CHINA/S (NASDAQ:HCM) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm own
HUTCHISON CHINA/S (NASDAQ:HCM) Rating Lowered to Hold at BidaskClub
07:32am, Saturday, 18'th Apr 2020
BidaskClub cut shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a buy rating to a hold rating in a report published on Tuesday, BidAskClub reports. Several other equities research analysts also recently
The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement
11:35am, Friday, 17'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 16.) * Abbott Laboratories (NYSE: ABT) (reacted to firs
